KR101004660B1 - 단삼 토탈 페놀릭 액시드의 제조 및 용도 - Google Patents
단삼 토탈 페놀릭 액시드의 제조 및 용도 Download PDFInfo
- Publication number
- KR101004660B1 KR101004660B1 KR1020047018929A KR20047018929A KR101004660B1 KR 101004660 B1 KR101004660 B1 KR 101004660B1 KR 1020047018929 A KR1020047018929 A KR 1020047018929A KR 20047018929 A KR20047018929 A KR 20047018929A KR 101004660 B1 KR101004660 B1 KR 101004660B1
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- column
- water
- extract
- total
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
군 | 투여량 mg/kg |
동물 수 | 경색 부피(%) | 물 함량(%) |
허위 조작 대조군 | 12 | 0 | 79.4586±0.3402** | |
허혈 대조군 | 10 | 7.0194±4.389 | 80.4487±0.8614 | |
Xiangdan 주사액 | 1 | 12 | 0.7553±2.2188** | 79.4364±0.5061*8 |
토탈 페놀릭 액시드 (Materia Medica 연구소) |
10 | 12 | 3.2919±3.205# | 79.4723±0.5475** |
토탈 페놀릭 액시드 (Materia Medica 연구소) |
20 | 12 | 1.5156±2.7602* | 79.4806±0.6819* |
토탈 페놀릭 액시드 (타슬리) |
10 | 10 | 2.8170±3.2621# | 79.4529±0.7693* |
토탈 페놀릭 액시드 (타슬리) |
20 | 10 | 1.5328±3.2575* | 79.5914±0.5843* |
Claims (19)
- 하기 단계를 포함하는 토탈 살비아놀릭 액시드(salvianolic acid)의 제조 방법:a) 단삼(Danshen)을 물로 추출하여 단삼 추출물을 제조하고, 상기 추출물을 산성화하고 여과하는 단계;b) 상기 단삼 추출물을 폴리아미드 컬럼에 적용하고, 상기 폴리아미드 컬럼을 물로 세척하여 중성 조건으로 하고, 상기 세척액을 폐기하고, 소듐 바이카보네이트 수용액을 이용하여 상기 폴리아미드 컬럼으로부터 용리된 분획을 수집하는 단계; 및c) 상기 폴리아미드 컬럼으로부터 용리된 분획을 산성화한 후에 흡착 수지 컬럼에 적용하고, 상기 흡착 수지 컬럼을 물로 세척하여 중성 조건으로 하고, 상기 세척액을 폐기한 다음, 알코올 수화물 또는 무수물을 이용하여 상기 홉착 수지 컬럼으로부터 용리액을 수집하고, 농축시키고, 건조하는 단계.
- 제1항에 있어서,상기 단계 a)에서 물에 의한 가열 추출을 각각 0.5~2 시간 동안 2~4 회 반복하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 a)의 물에 의한 추출 온도가 60~100℃인 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 a)의 물에 의한 추출 온도가 90~100℃인 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 a)의 추출물을 산으로 pH 4 이하로 조정하고, 상기 단계 c)의 폴리아미드 컬럼으로부터 용리된 분획을 산으로 pH 4 이하로 산성화하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 a)의 추출물을 산으로 pH 2 이하로 산성화하고, 상기 단계 c)의 폴리아미드 컬럼으로부터 용리된 분획을 염산 또는 황산으로 pH 2 이하로 산성화하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 b)에서 0.01~2%의 소듐 바이카보네이트 수용액을 용리액으로서 사용하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 b)에서 0.08~0.5%의 소듐 바이카보네이트 수용액을 용리액으로서 사용하는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 c)의 흡착 수지가 스티렌 타입인 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 c)에서 상기 컬럼을 저급 C1~C5 알코올 수화물 또는 무수물로 용리시키는 것을 특징으로 하는 방법.
- 제1항에 있어서,상기 단계 c)에서 상기 컬럼을 농도 40~95%의 수성 에탄올로 용리시키는 것을 특징으로 하는 방법.
- 제10항 또는 제11항에 있어서,상기 저급 C1-C5 알코올 또는 수성 에탄올의 농도가 60~95%인 것을 특징으로 하는 방법.
- 제11항에 있어서,상기 수성 에탄올의 농도가 95%인 것을 특징으로 하는 방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN02117923.9 | 2002-05-23 | ||
CNB021179239A CN1202103C (zh) | 2002-05-23 | 2002-05-23 | 丹参总酚酸的制备方法 |
PCT/CN2003/000375 WO2003099759A1 (fr) | 2002-05-23 | 2003-05-21 | Preparation et application d'acide transhintotalphenolique |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050024281A KR20050024281A (ko) | 2005-03-10 |
KR101004660B1 true KR101004660B1 (ko) | 2011-01-03 |
Family
ID=29426731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047018929A KR101004660B1 (ko) | 2002-05-23 | 2003-05-21 | 단삼 토탈 페놀릭 액시드의 제조 및 용도 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7641922B2 (ko) |
EP (1) | EP1506951B9 (ko) |
JP (1) | JP4570461B2 (ko) |
KR (1) | KR101004660B1 (ko) |
CN (1) | CN1202103C (ko) |
AT (1) | ATE424379T1 (ko) |
AU (1) | AU2003242135B8 (ko) |
CA (1) | CA2486378C (ko) |
DE (1) | DE60326450D1 (ko) |
DK (1) | DK1506951T3 (ko) |
ES (1) | ES2326165T3 (ko) |
RU (1) | RU2317973C2 (ko) |
WO (1) | WO2003099759A1 (ko) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100339085C (zh) | 2003-09-23 | 2007-09-26 | 天津天士力制药股份有限公司 | 治疗心脑血管疾病的中药组合物 |
CA2552311C (en) * | 2003-12-30 | 2013-04-23 | Md Bioalpha Co., Ltd. | Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity |
CN100372525C (zh) * | 2004-06-01 | 2008-03-05 | 广东天之骄生命科技有限公司 | 一种复方丹参冻干粉针剂及其制备方法 |
JP4633572B2 (ja) * | 2004-07-30 | 2011-02-16 | イスクラ産業株式会社 | 糖尿病改善剤 |
JP2010180250A (ja) * | 2004-07-30 | 2010-08-19 | Iskra Ind Co Ltd | 最終糖化産物生成抑制剤 |
JP4868199B2 (ja) * | 2004-09-10 | 2012-02-01 | 学校法人鈴鹿医療科学大学 | サルビアノール酸bを有効成分とする神経幹細胞増殖剤 |
JP2006232698A (ja) * | 2005-02-23 | 2006-09-07 | Suzuka Univ Of Medical Science | サルビアノール酸b等を主成分とする脳卒中又は脳卒中後遺症の予防用又は治療用薬剤 |
WO2006115321A1 (en) * | 2005-04-25 | 2006-11-02 | Industry Academic Cooperation Foundation, Yeungnam University | Composition comprising the extract of salvia miltiorrhiza bge showing enhancing activity for the prevention or treatment of blood circulatory disease. |
CN1919240B (zh) * | 2005-08-24 | 2011-02-16 | 天津天士力制药股份有限公司 | 治疗心脑血管疾病的中药 |
CN1919251B (zh) * | 2005-08-24 | 2010-11-03 | 天津天士力制药股份有限公司 | 治疗心血管疾病的中药组合物 |
KR100725839B1 (ko) * | 2005-10-06 | 2007-12-11 | 일성신약주식회사 | 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물 |
KR20070040209A (ko) * | 2005-10-11 | 2007-04-16 | 일성신약주식회사 | 단삼 분획물을 함유하는 인지기능 장애의 예방 및 치료용 조성물 |
CN101210002B (zh) * | 2006-12-27 | 2011-04-20 | 中国科学院大连化学物理研究所 | 一种丹酚酸b化学对照品的分离制备方法 |
CN101721468B (zh) * | 2008-10-21 | 2013-02-13 | 天津天士力之骄药业有限公司 | 一种丹参总酚酸制备方法 |
CN101401843B (zh) * | 2008-11-18 | 2011-10-05 | 阳国平 | 一种中药丹参有效成分的提取方法 |
JP5755633B2 (ja) * | 2009-03-30 | 2015-07-29 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドTasly Pharmaceutical Group Co., Ltd. | 新規サルビアノール酸化合物l、その調製方法及び使用 |
KR20130073938A (ko) * | 2010-08-06 | 2013-07-03 | 타슬리 파마슈티컬 그룹 컴퍼니 리미티드 | 관상 동맥성 심장병의 2차 예방을 위한 약의 조제에 있어서 단삼 조성물의 용도 |
CN104418744B (zh) * | 2013-08-29 | 2017-03-01 | 天士力制药集团股份有限公司 | 一种新的丹酚酸化合物t、其制备方法和用途 |
CN107951981A (zh) * | 2017-12-30 | 2018-04-24 | 黄旭东 | 一种筋骨伤涂剂及其制备方法 |
CN112315997B (zh) * | 2020-11-30 | 2022-03-25 | 四川省中医药科学院 | 一种丹参和葛根提取物的固体分散体及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6299910B1 (en) * | 1999-04-07 | 2001-10-09 | Techical Sourcing International, Inc. | Methods for identification, purification, and manufacturing of the active constituent in Salvia-miltiorrhiza (dansheng) and the application of this product in enhancing cardiovascular functions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001505583A (ja) * | 1996-12-05 | 2001-04-24 | ジョージタウン ユニヴァーシティー | 抗ウイルス活性を有するサルビア種の抽出物 |
US6043276A (en) * | 1998-06-25 | 2000-03-28 | Georgetown University School Of Medicine | Compounds obtained from salvia species having antiviral activity |
CN1129572C (zh) * | 1998-09-11 | 2003-12-03 | 中国科学院上海药物研究所 | 丹参多酚酸盐混合物及其制备方法和用途 |
CN1163227C (zh) | 1999-04-19 | 2004-08-25 | 上海中医药大学 | 丹酚酸b镁盐在制备治疗慢性肝病药剂中的应用 |
CN1229324C (zh) | 2001-09-26 | 2005-11-30 | 中国医学科学院药物研究所 | 丹参总酚酸的提取方法及其制剂的制法与用途 |
CN1161317C (zh) | 2001-09-27 | 2004-08-11 | 华东理工大学 | 从植物丹参中提取纯化丹参素的方法 |
-
2002
- 2002-05-23 CN CNB021179239A patent/CN1202103C/zh not_active Expired - Lifetime
-
2003
- 2003-05-21 KR KR1020047018929A patent/KR101004660B1/ko active IP Right Grant
- 2003-05-21 US US10/515,963 patent/US7641922B2/en active Active
- 2003-05-21 WO PCT/CN2003/000375 patent/WO2003099759A1/zh active Application Filing
- 2003-05-21 RU RU2004136577/04A patent/RU2317973C2/ru active
- 2003-05-21 CA CA2486378A patent/CA2486378C/en not_active Expired - Lifetime
- 2003-05-21 EP EP03732181A patent/EP1506951B9/en not_active Expired - Lifetime
- 2003-05-21 DK DK03732181T patent/DK1506951T3/da active
- 2003-05-21 AU AU2003242135A patent/AU2003242135B8/en not_active Expired
- 2003-05-21 ES ES03732181T patent/ES2326165T3/es not_active Expired - Lifetime
- 2003-05-21 DE DE60326450T patent/DE60326450D1/de not_active Expired - Lifetime
- 2003-05-21 AT AT03732181T patent/ATE424379T1/de active
- 2003-05-21 JP JP2004507417A patent/JP4570461B2/ja not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6299910B1 (en) * | 1999-04-07 | 2001-10-09 | Techical Sourcing International, Inc. | Methods for identification, purification, and manufacturing of the active constituent in Salvia-miltiorrhiza (dansheng) and the application of this product in enhancing cardiovascular functions |
Non-Patent Citations (2)
Title |
---|
Chem. Pharm. Bull. 36(1) 316-320 (1988)* |
Journal of Chromatography A, 943 (2002) 235-239* |
Also Published As
Publication number | Publication date |
---|---|
CA2486378C (en) | 2011-02-22 |
CA2486378A1 (en) | 2003-12-04 |
RU2317973C2 (ru) | 2008-02-27 |
JP4570461B2 (ja) | 2010-10-27 |
EP1506951A1 (en) | 2005-02-16 |
KR20050024281A (ko) | 2005-03-10 |
DK1506951T3 (da) | 2009-05-25 |
US20050159491A1 (en) | 2005-07-21 |
EP1506951B1 (en) | 2009-03-04 |
EP1506951B9 (en) | 2009-08-26 |
AU2003242135B2 (en) | 2009-08-27 |
RU2004136577A (ru) | 2005-06-27 |
CN1202103C (zh) | 2005-05-18 |
WO2003099759A8 (fr) | 2004-03-11 |
AU2003242135A1 (en) | 2003-12-12 |
AU2003242135B8 (en) | 2009-12-03 |
US7641922B2 (en) | 2010-01-05 |
JP2005538055A (ja) | 2005-12-15 |
EP1506951A4 (en) | 2005-08-03 |
WO2003099759A1 (fr) | 2003-12-04 |
ATE424379T1 (de) | 2009-03-15 |
ES2326165T3 (es) | 2009-10-02 |
DE60326450D1 (de) | 2009-04-16 |
CN1459448A (zh) | 2003-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101004660B1 (ko) | 단삼 토탈 페놀릭 액시드의 제조 및 용도 | |
KR102193363B1 (ko) | 신규 살비아놀산 화합물 t, 그 제조 방법, 및 용도 | |
EP2415749B1 (en) | New salvianolic acid compound l, preparation method and use thereof | |
AU2014289766B2 (en) | Traditional chinese medicine composition, and preparation and application thereof | |
EP3020408B1 (en) | Traditional chinese medicine composition, and preparation and application thereof | |
EP3040077A1 (en) | Traditional chinese medicine composition | |
WO2008145064A1 (fr) | Procédé d'obtention d'un extrait contenant du séquoyitol à partir d'une espèce du genre trifolium, de soja et de ginkgo biloba, et utilisation de celui-ci | |
CN106432385A (zh) | 一种高纯度灯盏花素提取物及制剂的制备方法及用途 | |
CN111000903A (zh) | 一种治疗血瘀型冠心病心绞痛的中药组合物及其制备方法 | |
CN101293009A (zh) | 药物组合物 | |
JPH02142723A (ja) | 腎障害改善剤 | |
CN101721468B (zh) | 一种丹参总酚酸制备方法 | |
CN101342236A (zh) | 丹参提取物的制法、丹参提取物和含有其的药物组合物 | |
CN118271275A (zh) | 具有抑制寨卡病毒活性的二聚鸡脚参素A~E及taxodascens J的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131129 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20141201 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151118 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171117 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181115 Year of fee payment: 9 |